Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005

doi:10.3201/eid1411.080337

Comparative Study

. 2008 Nov;14(11):1756-8.

doi: 10.3201/eid1411.080337.

Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005

Marya D Zilberberg¹, Andrew F Shorr, Marin H Kollef

Affiliations

PMID: 18976563
PMCID: PMC2630735
DOI: 10.3201/eid1411.080337

Comparative Study

Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005

Marya D Zilberberg et al. Emerg Infect Dis. 2008 Nov.

. 2008 Nov;14(11):1756-8.

doi: 10.3201/eid1411.080337.

Authors

Marya D Zilberberg¹, Andrew F Shorr, Marin H Kollef

Affiliation

¹ EviMed Research Group, LLC, Goshen, Massachussetts 01032, USA. marya@evimedgroup.org

PMID: 18976563
PMCID: PMC2630735
DOI: 10.3201/eid1411.080337

Abstract

From 2000 through 2005, hospitalizations with resistant infections (methicillin-resistant Staphylococcus aureus, Clostridium difficile-associated disease, vancomycin-resistant enterococcus, Pseudomonas aeruginosa, and Candida infection) nearly doubled, from 499,702 to 947,393. Regional variations noted in the aggregate and by individual infection may help clarify modifiable risk factors driving these infections.

PubMed Disclaimer

Figures

**Figure**
Population incidence of component resistant infections in the United States, by census region, 2000–2005. A) *Clostridium difficile–*associated disease; B) methicillin-resistant *Staphylococcus aureus*; C) vancomycin-resistant enterococcus; D) *Pseudomonas aeruginosa*; E) *Candida* spp.

See this image and copyright information in PMC

Cited by

The Prevalence and Molecular Biology of Staphylococcus aureus Isolated from Healthy and Diseased Equine Eyes in Egypt.
Tahoun A, Elnafarawy HK, El-Sharkawy H, Rizk AM, Alorabi M, El-Shehawi AM, Youssef MA, Ibrahim HMM, El-Khodery S. Tahoun A, et al. Antibiotics (Basel). 2022 Feb 10;11(2):221. doi: 10.3390/antibiotics11020221. Antibiotics (Basel). 2022. PMID: 35203823 Free PMC article.
IL-17-producing γδ T cells protect against Clostridium difficile infection.
Chen YS, Chen IB, Pham G, Shao TY, Bangar H, Way SS, Haslam DB. Chen YS, et al. J Clin Invest. 2020 May 1;130(5):2377-2390. doi: 10.1172/JCI127242. J Clin Invest. 2020. PMID: 31990686 Free PMC article.
Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
Alhifany AA, Almutairi AR, Almangour TA, Shahbar AN, Abraham I, Alessa M, Alnezary FS, Cheema E. Alhifany AA, et al. BMJ Open. 2019 Nov 7;9(11):e031145. doi: 10.1136/bmjopen-2019-031145. BMJ Open. 2019. PMID: 31699731 Free PMC article.
Burden of hospitalizations over time with invasive aspergillosis in the United States, 2004-2013.
Zilberberg MD, Harrington R, Spalding JR, Shorr AF. Zilberberg MD, et al. BMC Public Health. 2019 May 17;19(1):591. doi: 10.1186/s12889-019-6932-9. BMC Public Health. 2019. PMID: 31101036 Free PMC article.
Modeling Clostridium difficile in a hospital setting: control and admissions of colonized and symptomatic patients.
Chamchod F, Palittapongarnpim P. Chamchod F, et al. Theor Biol Med Model. 2019 Jan 31;16(1):2. doi: 10.1186/s12976-019-0098-0. Theor Biol Med Model. 2019. PMID: 30704484 Free PMC article.

See all "Cited by" articles

References

1. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840–6. - PMC - PubMed
1. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile–related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:929–31. 10.3201/eid1411.080337 - DOI - PMC - PubMed
1. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788–94. 10.1093/jac/dkm258 - DOI - PubMed
1. Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection. 2007;35:300–7. 10.1007/s15010-007-6113-0 - DOI - PubMed
1. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–74. 10.1056/NEJMoa055356 - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- MedlinePlus Health Information

[1] Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840–6. - PMC - PubMed

[2] Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840–6. - PMC - PubMed

[3] Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile–related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:929–31. 10.3201/eid1411.080337 - DOI - PMC - PubMed

[4] Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile–related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:929–31. 10.3201/eid1411.080337 - DOI - PMC - PubMed

[5] Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788–94. 10.1093/jac/dkm258 - DOI - PubMed

[6] Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788–94. 10.1093/jac/dkm258 - DOI - PubMed

[7] Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection. 2007;35:300–7. 10.1007/s15010-007-6113-0 - DOI - PubMed

[8] Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection. 2007;35:300–7. 10.1007/s15010-007-6113-0 - DOI - PubMed

[9] Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–74. 10.1056/NEJMoa055356 - DOI - PubMed

[10] Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–74. 10.1056/NEJMoa055356 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005

Affiliation

Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005

Authors

Affiliation

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical